Introducing A NEW Drug Monitoring Assay | Anti-Vedolizumab (Entyvio®)

Posted by Brandon Savela on May 31st 2017

This message is to inform you about a new development concerning our ImmunoGuide® Drug Monitoring product range.

We are pleased to present our new Anti-Vedolizumab (Entyvio®) ELISA kit!

The drug Vedolizumab (trade name Entyvio®) is a humanised immunoglobulin G1 monoclonal antibody that binds exclusively to the lymphocyte integrin α4β7, is indicated for the treatment of moderately to severely active ulcerative colitis [UC] or Crohn’s disease [CD]. During treatment the presence of persistent anti-Vedolizumab antibody was observed to substantially reduce serum concentrations of Vedolizumab, either to undetectable or negligible levels. The ImmunoGuide Antibody to Vedolizumab ELISA kit has been designed for the measurement of free antibodies against this drug. It does not detect such antibodies which already are bound to the drug.

Enzyme immunoassay for the semi-quantitative determination of free antibodies to Vedolizumab (Entyvio®) in serum and plasma. For research use only - not for use in diagnostic procedures.

Catalog Number	IG-BB116
Species	Human
Design	Enzyme immunoassay (ELISA) technique.
Standards	Negative control is used to determine a cut-off value for the evaluation of results.
Controls	Positive and negative controls, ready to use.
Sample Types	Serum and plasma.
Sample Volume	10 µL
Assay Desc.	1 hour incubation (RT) + 1 hour (RT) + 15 min. (RT) = 2 hour, 15 min. total incubation time.
Standard Range	Negative control is used to determine a cut-off value for the evaluation of results.
Sensitivity	10 ng/mL
Storage	2 - 8 °C